© Provided by AFPRelaxNews Migraine sufferers could be at an increased risk of certain heart problems according to new research.New international research has found that migraine sufferers may also have an increased risk of cardiovascular problems including heart attacks, stroke, blood clots, and an irregular heart rate.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. On Monday, the company revealed Phase IIIb data that demonstrated the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. Additionally, the FDA has granted fast track designation for fremanezumab for the prevention of cluster headache.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.